Serum Glucose and Fructosamine in Relation to Risk of Cancer
Open Access
- 25 January 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (1) , e54944
Abstract
Impaired glucose metabolism has been linked with increased cancer risk, but the association between serum glucose and cancer risk remains unclear. We used repeated measurements of glucose and fructosamine to get more insight into the association between the glucose metabolism and risk of cancer. We selected 11,998 persons (>20 years old) with four prospectively collected serum glucose and fructosamine measurements from the Apolipoprotein Mortality Risk (AMORIS) study. Multivariate Cox proportional hazards regression was used to assess standardized log of overall mean glucose and fructosamine in relation to cancer risk. Similar analyses were performed for tertiles of glucose and fructosamine and for different types of cancer. A positive trend was observed between standardized log overall mean glucose and overall cancer risk (HR = 1.08; 95% CI: 1.02–1.14). Including standardized log fructosamine in the model resulted in a stronger association between glucose and cancer risk and aninverse association between fructosamine and cancer risk (HR = 1.17; 95% CI: 1.08–1.26 and HR: 0.89; 95% CI: 0.82–0.96, respectively). Cancer risks were highest among those in the highest tertile of glucose and lowest tertile of fructosamine. Similar findings were observed for prostate, lung, and colorectal cancer while none observed for breast cancer. The contrasting effect between glucose, fructosamine, and cancer risk suggests the existence of distinct groups among those with impaired glucose metabolism, resulting in different cancer risks based on individual metabolic profiles. Further studies are needed to clarify whether glucose is a proxy of other lifestyle-related or metabolic factors.Keywords
This publication has 42 references indexed in Scilit:
- A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal womenBritish Journal of Cancer, 2011
- Premenopausal endogenous oestrogen levels and breast cancer risk: a meta-analysisBritish Journal of Cancer, 2011
- Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal CancerCancer Epidemiology, Biomarkers & Prevention, 2011
- Glycated Hemoglobin Predicts All-Cause, Cardiovascular, and Cancer Mortality in People Without a History of Diabetes Undergoing Coronary AngiographyDiabetes Care, 2011
- Evidence That Serum Levels of the Soluble Receptor for Advanced Glycation End Products Are Inversely Associated with Pancreatic Cancer Risk: A Prospective StudyCancer Research, 2011
- Insulin-Mediated Acceleration of Breast Cancer Development and Progression in a Nonobese Model of Type 2 DiabetesCancer Research, 2010
- Blood Glucose and Risk of Incident and Fatal Cancer in the Metabolic Syndrome and Cancer Project (Me-Can): Analysis of Six Prospective CohortsPLOS Medicine, 2009
- A cohort study of the risk of cancer associated with type 2 diabetesBritish Journal of Cancer, 2009
- RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and InflammationJournal of Translational Medicine, 2009
- Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysisThe Lancet, 2004